<DOC>
	<DOCNO>NCT00124982</DOCNO>
	<brief_summary>The purpose study summarize safety tolerability abatacept 6 month combine treatment one background non-biologic disease modify anti-rheumatic drug ( DMARDs ) approve rheumatoid arthritis ( RA ) subject active RA . Secondary objective assess clinical efficacy combination treatment , include disease activity , physical function , quality life outcome .</brief_summary>
	<brief_title>Study Abatacept ( BMS-188667 ) Subjects With Active Rheumatoid Arthritis Background Non-biologic DMARDS ( Disease Modifying Antirheumatic Drugs ) Who Have Inadequate Response Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Completed doubleblind portion IM101064 study . Rheumatoid arthritis ( RA ) great 1 year time initial diagnosis American College Rheumatology ( ACR ) functional class I , II , III Subjects currently previously receive antiTNF therapy approve label dose least 3 month Subjects active vasculitis major organ system ( except subcutaneous rheumatoid nodule ) History cancer within last 5 year ( nonmelanoma skin cell cancer cure local resection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>